ESMO 2019 | TROPHY-U-01: Initial findings

Scott Tagawa

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial results from the TROPHY-U-01 phase II trial, assessing the efficacy and toxicities in the first cohort of patients (those who have already received platinum-based chemotherapy and immune checkpoint based therapy) with sacituzumab govitecan. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video